Volume 4.00 | Jan 5

Human Immunology News 4.00 January 5, 2016
Human Immunology News
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Like Us on Facebook   HIN on Twitter
 
TOP STORY
RSV-Specific Airway Resident Memory CD8+ T Cells and Differential Disease Severity after Experimental Human Infection
Using experimental human respiratory syncytial virus (RSV) infection, researchers investigated systemic and local virus-specific CD8+ T-cell responses in adult volunteers. [Nat Commun] Full Article
Free Sample: The Only Kit to Isolate Th17 Cells Without Cell Activation
 
PUBLICATIONS (Ranked by impact factor of the journal)
FOXP3 Can Modulate TAL1 Transcriptional Activity through Interaction with LMO2
The authors showed that increased forkhead box P3 (FOXP3) levels negatively correlate with expression of genes regulated by the oncogenic T-cell acute lymphocytic leukemia 1 (TAL1)-complex in human T-cell acute lymphoblastic leukemia (T-ALL) patient samples as well as a T-ALL cell line ectopically expressing FOXP3. [Oncogene] Abstract

Antibody Induced CD4 Down-Modulation of T Cells Is Site-Specifically Mediated by CD64+ Cells
Treatment of PBMC with the CD4-specific monoclonal antibody BT-061 induces CD4 down-modulation of T cells. Scientists report that addition of BT-061 to purified T cells did not confer this effect, whereas incubation of T cells in BT-061 coated wells restored CD4 down-modulation. [Sci Rep] Full Article

Accumulation Mechanisms of CD4+CD25+FOXP3+ Regulatory T Cells in EBV-Associated Gastric Carcinoma
Because regulatory T cells (Tregs) are regarded as a critical hurdle in anti-tumour immunity, researchers assessed the distribution of Tregs in 45 cases of Epstein-Barr virus (EBV)-associated gastric carcinomas and 45 cases of EBV-negative gastric carcinoma with matched clinicopathological parameters by immunohistochemistry. [Sci Rep] Full Article

Identification of a Novel Mechanism of Action of Fingolimod (FTY720) on Human Effector T Cell Function through TCF-1 Upregulation
Researchers determined the effect of FTY720 on human T cell activation and effector function. They showed that FTY720 treatment not only affects T cell trafficking but also T cell activation. [J Neuroinflammation] Full Article

LZTFL1 Upregulated by All-Trans Retinoic Acid during CD4+ T Cell Activation Enhances IL-5 Production
The authors investigated the gene expression profile of all-trans retinoic acid (ATRA)–treated human CD4+ T cells. Leucine zipper transcription factor-like 1 (LZTFL1) was upregulated by ATRA in a dose- and time-dependent manner. [J Immunol] Abstract

The Notch Ligand DLL4 Defines a Capability of Human Dendritic Cells in Regulating Th1 and Th17 Differentiation
Researchers report the identification of human DLL4+ dendritic cells (DCs) and their critical role in regulating Th1 and Th17 differentiation. CD1c+ DCs and plasmacytoid DCs from the peripheral blood of healthy donors did not express DLL4. [J Immunol] Abstract

Human Regulatory T Cells Control TCR Signaling and Susceptibility to Suppression in CD4+ T Cells
Scientists demonstrated that T cell receptors and costimulation are required to activate the regulatory T cell suppressive function. Regulatory T cells suppressed the T cell receptor signaling in effector T cells in a time-dependent manner that corresponded with inhibition of cytokine production and proliferation. [J Leukoc Biol] Abstract

Hypomethylation of the Treg-Specific Demethylated Region in FOXP3 Is a Hallmark of the Regulatory T-Cell Subtype in Adult T-Cell Leukemia
The authors focus on the functional and clinical relationship between the epigenetic pattern of the Treg-specific demethylated region (TSDR) and adult T-cell leukemia (ATL). Analysis of DNA methylation in specimens from 26 ATL patients showed that 15 patients hypomethylated the TSDR. [Cancer Immunol Res] Abstract

Association of Depressed Anti-HER2 T-Helper Type 1 Response with Recurrence in Patients with Completely Treated HER2-Positive Breast Cancer
Investigators determined whether circulating anti-human epidermal growth factor receptor 2 (HER2) CD4-positive T-helper type 1 immunity correlates with recurrence in patients with completely treated HER2-positive invasive breast cancer. [JAMA Oncol] Abstract | Press Release

Subscribe to our sister publications: Immunology of Infectious Disease News & Immune Regulation News!

Fast and Easy, Column-Free Magnetic Immune Cell Isolation. Learn more.
 
REVIEWS
Regulatory T Cell Memory
The authors consider the parallels between memory effector T cells and memory regulatory T cells, along with the functional implications of regulatory memory in autoimmunity, antimicrobial host defence and maternal–fetal tolerance. In addition, they discuss emerging evidence for regulatory T cell memory in humans and key unanswered questions in this rapidly evolving field. [Nat Rev Immunol] Abstract

Tissue-Resident Memory T Cells: Local Specialists in Immune Defence
The author discuss the major advances and the emerging concepts in this field, summarize what is known about the differentiation and the protective functions of tissue-resident memory T cells in different tissues in the body and highlight key unanswered questions. [Nat Rev Immunol] Abstract

Visit our reviews page to see a complete list of reviews in the human immunology research field.
 
INDUSTRY NEWS
Baxalta and Symphogen Establish Strategic Collaboration to Accelerate Innovation in Immuno-Oncology
Baxalta Incorporated and Symphogen announced a broad strategic immuno-oncology collaboration. Under the terms of the agreement, Baxalta and Symphogen will advance novel therapeutics against six checkpoint targets, with the first program to enter clinical studies in 2017. [Baxalta] Press Release

OSE Pharma Announces Selection of 70 International Clinical Centers to Participate in Its Pivotal Phase III Trial of Tedopi® for Patients Diagnosed with Advanced Non-Small Cell Lung Cancer (NSCLC)
OSE Pharma SA announced that it finalized the selection of the 70 investigator centers, in Europe and the United States, to participate in its pivotal Phase III clinical trial of Tedopi®. [OSE Pharma SA (Business Wire)] Press Release

MabVax Therapeutics Announces FDA Authorization to Proceed with HuMab-5B1 in a Phase I Clinical Trial for the Treatment for Pancreatic Cancer
MabVax Therapeutics Holdings, Inc. announced that it has received notice from the U.S. Food and Drug Administration (FDA) authorizing the initiation a Phase I clinical trial with HuMab-5B1 as a therapeutic treatment for pancreatic cancer. [MabVax Therapeutics Holdings, Inc.] Press Release

From our sponsor: Working with blood? Request your free wallchart on human blood cell frequencies.
 
POLICY NEWS
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
 
EVENTS
NEW Immunology 2016
May 13-17, 2016
Seattle, United States

Visit our events page to see a complete list of events in the human immunology community.
 
JOB OPPORTUNITIES
NEW Postdoctoral Position – Immunology (VIB)

NEW Postdoctoral Fellow – Cell Therapy (Toronto Western Hospital)

NEW Postdoctoral Research Fellow – Immunology (Victoria University of Wellington)

NEW Postdoctoral Research Associate – Clinical Immunology (Benaroya Research Institute at Virginia Mason)

NEW Postdoctoral Position – Immunology (Boston Children’s Hospital and Harvard Medical School)

NEW Postdoctoral Positions – Hantavirus and Inflammation Research (Karolinska Institutet)

NEW Faculty Position – Immunotherapy (Fox Chase Cancer Center)

NEW Postdoctoral Position – Quantitative Proteomics, Phosphoproteomics and Immune-Cell Signaling (University of Southern Denmark)

Senior Scientist – Immunology and Cell Separation (STEMCELL Technologies Inc.)

Postdoctoral Position – Immunology & Bioimaging (University Hospital Würzburg)

Postdoctoral Fellow – Cancer Immunotherapy (Inserm)


Recruit Top Talent: Reach more than 60,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
 

Have we missed an important article or publication in Human Immunology News? Click here to submit!

Comments or suggestions? Submit your feedback here
Learn more about Human Immunology News: Archives | Events | Contact Us